Meprobamate (2-methyl-2-n-propyl-1,3-propanediol dicarbamate [Miltown, Equanil]) has become widely used as an ataractic
or tranquilizing drug since its clinical introduction in 1955. The rarity and mildness
of its side-effects, as described in early reports of clinical trials,1,2 encouraged its
liberal use in many conditions characterized
by anxiety and tension. In recent months,
however, numerous reports of untoward reactions to this drug have appeared in the
literature. We wish to present a case which
we strongly suspect of representing a fatal
reaction to meprobamate.
Report of Case
A 50-year-old white housewife entered the
Albert Einstein Medical Center, Northern Division,
on Aug. 14, 1957, at 11:30 p. m., complaining of
fever, nausea and vomiting, and a widespread
erythematous rash.Fourteen days before admission the patient had
taken for the first time 2 or 3 tablets of Meprolone-2 (2 mg. of prednisolone, 200 mg. of meprobamate, and 200 mg. of dried aluminum hydroxide
gel), which had been
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
* * SCHEDULED MAINTENANCE * *
Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.